



Press Release April 25, 2023

## **Genovis Annual Report 2022 published**

**Genovis 2022 Annual Report is now available in Swedish and English at our website.**

**To read or download the annual report in Swedish, go to:**

[https://investor.genovis.com/wp-content/uploads/Genovis\\_AR\\_2022\\_Sv.pdf](https://investor.genovis.com/wp-content/uploads/Genovis_AR_2022_Sv.pdf)

**To read or download the annual report in English, go to:**

[https://investor.genovis.com/wp-content/uploads/Genovis\\_AR\\_2022\\_En.pdf](https://investor.genovis.com/wp-content/uploads/Genovis_AR_2022_En.pdf)

For more information, please contact:

Fredrik Olsson, CEO, Genovis AB

T: +46 (0)46-10 12 33

E: [fredrik.olsson@genovis.com](mailto:fredrik.olsson@genovis.com)

**Genovis'** business concept is to apply its knowledge and imagination to design and provide innovative tools for development of the drugs of the future. Today Genovis sells several enzyme products known as SmartEnzymes™ all over the world in innovative product formats that facilitate development and quality control of biological drugs.

The Group consists of Genovis AB and the wholly owned subsidiary Genovis Inc. (US). Genovis' shares are listed on Nasdaq First North Growth Market and Erik Penser Bank is the Company's Certified Adviser, [certifiedadviser@penser.se](mailto:certifiedadviser@penser.se), tel: +46 (0)8-463 83 00.